ArticleJournal of the American Association for Laboratory Animal Science : JAALAS2025
Lessons Learned from Monitoring Adeno-Associated Virus-9 Neutralizing Antibody (AAV9-NAb) Seroconversion in a Cohort of Cynomolgus Macaques (Macaca fascicularis).
Article in Journal of the American Association for Laboratory Animal Science : JAALAS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this study was to track seroconversion in a cohort of 12, pair-housed, macaques that were previously screened negative for adeno-associated virus-9 neutralizing antibody (AAV9-NAb). Over a 6-month period, specific biosecurity strategies were implemented with the intention of understanding if following defined protocols could play a role in preservation of AAV9-NAb negative status. AAV9-NAb-negative animals were selected for shipment to the facility approximately 2 months after the initial screening. After arrival, animals were paired and housed in a single room with a dedicated housing corridor, cage wash, and equipment. They were then screened for AAV9-NAb status monthly by 2 different labs to confirm results and ascertain potential for variation of results. Upon initial screening at the facility (within one week of arrival), 2 of the 12 NHPs that were seronegative before shipment had seroconverted to AAV9-NAb positive status. The positive animals and their negative partners were moved to a different room but remained within the same isolated corridor with the same biosecurity practices. Serum that was taken on a monthly basis was also used to screen other AAVs. At the end of the 6-month period, AAV9 NAb status did not change from the time the animals were initially screened on site until the end of the study. Paired animals that were cohoused in the same cage with a positive partner did not seroconvert. Although a control group was not used to validate that biosecurity practices played a role in mitigating seroconversion, unpublished data from a facility employing less restricted biosecurity strategies suggest that the seroconversion process involves a more intricate process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.